Published in Vaccine Weekly, July 3rd, 2002
J.A. Sosman and colleagues at the Southwest Oncology Group, an organization involved in multicenter adult cancer clinical trials in the U.S. and Canada, performed a randomized, observation-control led clinical trial to investigate a reported link between expression of HLA class I antigens (HLA-A2, HLA-A28, HLA-B44, HLA-B45, and HLA-C3) and the success of an allogeneic cancer vaccine (Melacine, Corixa Corp., Seattle). The antigen group...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.